Intestine and Lower Gastrointestinal Tract · 22 August 2025

Immune Checkpoint Inhibitors Triple Pathological Response in Locally Advanced Rectal Cancer

Neoadjuvant immune checkpoint inhibitors boost pathological complete response rates in locally advanced rectal cancer, ranging from 25-62.5%. The clinical complete response rates also soared—hitting 100% in some cases of dMMR/MSI-H tumors. Sphincter preservation rates reached up to 100%. Despite promising outcomes, the evidence stems from a limited number of phase I/II trials without long-term survival data, highlighting the need for robust studies to verify these gains.

Journal Article by Mui M, Kong JC (…) Heriot AG et 3 al. in Dis Colon Rectum

read the whole article in Dis Colon Rectum

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

Br J Surg4 Nov 2026

Robot matches laparoscopy for rectal cancer survival

Five years after surgery for low rectal cancer, patients operated on robotically did as well as those operated on laparoscopically, according to a randomized trial from three Korean centres.

Ann Surg Oncol2 Nov 2026

Smoking linked to weaker rectal cancer response

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

All papers in Intestine and Lower Gastrointestinal Tract →